GSK to buy Nuvalent for $10.6B, snagging two experimental lung-cancer drugs
GSK plans a $10.6 billion acquisition of Nuvalent to gain two experimental lung-cancer medicines (Zidesamtinib and Neladalkib) currently under FDA review, bolstering its oncology pipeline amid a major biotech deal.